Affiliated Society: Society for Biomaterials
Country of Residence: USA
Current Position: Professor
Kinam Park received his Ph.D. degree in pharmaceutics from University of Wisconsin in 1983. After postdoctoral training at the Department of Chemical Engineering of the same university, he joined the faculty of Purdue University in 1986 and promoted to Full Professor of Pharmaceutics in 1994. Since 1998, he has also had a joint appointment in the Department of Biomedical Engineering, and became Showalter Distinguished Professor of Biomedical Engineering in 2006.
He has published 260 peer-reviewed papers, 100 book chapters, 160 JCR cover stories, and 100 proceedings. He presented 200 abstracts at meetings and 270 invited lectures. He published 12 books in the area of controlled drug delivery. He has trained 120 Ph.D. graduate students, postdoctoral fellows and visiting scientists. He received many awards including Clemson Award of Society for Biomaterials and Controlled Release Society Founders Award. He founded Akina, Inc., specializing in drug delivery technologies in 2001. Currently, the company produces more than 500 specialty polymers for supply throughout the world. He is an editorial board member of 20 journals, and he is currently the Editor-in-Chief of the Journal of Controlled Release (JCR).
Areas of research interest:
He has studied drug delivery systems for more than three decades, and his research has been focused on four specific areas of controlled drug delivery: (1) oral delivery systems using polymers and hydrogels, such as fast-dissolving tablets, oral sustained release formulations, gastric retention devices, and hydrotropic polymers for delivery of poorly soluble drugs; (2) cancer targeting of intravenously administered adaptable nanoparticles, including crosslinked polymer micelles and surface modified drug crystals; (3) local delivery from implantable devises, e.g., drug-eluting stents and balloons; and (4) microencapsulation of various drugs ranging from small hydrophobic drugs to hydrophilic peptide/protein drugs using microfabrication; Recently, he started a new research topic entitled “Digital human for drug development”. This project deals with computer simulation of drug release from dosage forms and subsequent physiology based pharmacokinetic modeling using a virtual human model.